RNA
Avidity Biosciences, Inc.
Avidity Biosciences, Inc. (RNA) has 19 SEC Form 4 filings (24 transaction rows) in the rolling window, disclosed by 8 distinct insiders. Most recent filing: Apr 22, 2026.
Insiders have net sold $4.2M over the trailing 6 months.
- Industry:Biotechnology
- CEO:Kathleen Gallagher
- Employees:511
- HQ:San Diego, CA, US
- IPO:2026-02-27
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$4.2M
reported sales (SEC code S)
Unique Insiders
8
in the rolling window
| Source | ||||||
|---|---|---|---|---|---|---|
| Chief Scientific Officer | Sale | 6,534 | $473K | Jan 23 | SEC ↗ | |
| Chief Financial Officer | Sale | 4,542 | $329K | Jan 23 | SEC ↗ | |
| Chief Human Resources Officer | Sale | 2,929 | $212K | Jan 23 | SEC ↗ | |
| Chief Medical Officer | Sale | 4,895 | $355K | Jan 23 | SEC ↗ | |
| President and CEO | Sale | 14,387 | $1.0M | Jan 23 | SEC ↗ | |
LEVIN ARTHUR AFirst filing | Director | Sale | 1,758 | $127K | Jan 23 | SEC ↗ |
MacLean Michael FFirst filing | Chief Financial Officer | Sale | 1,974 | $143K | Jan 9 | SEC ↗ |
McCarthy TeresaFirst filing | Chief Human Resources Officer | Sale | 1,965 | $142K | Jan 9 | SEC ↗ |
Hughes Steven GeorgeFirst filing | Chief Medical Officer | Sale | 2,373 | $171K | Jan 9 | SEC ↗ |
Flanagan W. MichaelFirst filing | Chief Scientific Officer | Sale | 2,373 | $171K | Jan 9 | SEC ↗ |
Boyce SarahFirst filing | President and CEO | Sale | 8,576 | $619K | Jan 9 | SEC ↗ |
Moriarty John BFirst filing | Chief Legal Officer | Sale | 2,374 | $171K | Jan 9 | SEC ↗ |
Calderaro Charles IIIFirst filing | Chief Technical Officer | Sale | 3,727 | $269K | Jan 9 | SEC ↗ |
Related companies
Avidity Biosciences, Inc. is in the Healthcare sector.